By Connor Hart
Shares of Surmodics jumped after a federal court denied a request from the Federal Trade Commission and state regulators to block the company's proposed acquisition by GTCR.
Shares climbed 49% to $40.77 in morning trading Tuesday. The stock is up 6% over the past year.
The medical-device maker said late Monday that the U.S. District Court for the Northern District of Illinois declined to issue a preliminary injunction that would have prevented the two sides from closing the transaction.
The ruling marks "a significant step toward being able to complete the merger, which we continue to believe will position the company to continue to deliver compelling benefits for physicians, patients and customers going forward," Chief Executive Gary Maharaj said.
Surmodics and GTCR are still bound by a temporary restraining order that bars them from completing the merger before 5 p.m. CT on Nov. 17, Surmodics said. The deal also remains subject to customary closing conditions, including the absence of any other legal prohibitions.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 11, 2025 10:20 ET (15:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.